Presentation is loading. Please wait.

Presentation is loading. Please wait.

Leksell Gamma Knife® Treatment Statistics Report

Published byVictoria Watkins Modified over 6 years ago

Similar presentations

Presentation on theme: "Leksell Gamma Knife® Treatment Statistics Report"— Presentation transcript:

1 Leksell Gamma Knife® Treatment Statistics Report 1968-2016

2

3 Leksell Gamma Knife® OVER 1 040 000 PATIENTS TREATED THROUGH 2016, WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

4 INDICATIONS TREATED ANNUALLY THROUGH 2016, WORLDWIDE
Leksell Gamma Knife® INDICATIONS TREATED ANNUALLY THROUGH 2016, WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

5 Leksell Gamma Knife® CHANGE IN AVERAGE VOLUME PER CENTER, WORLDWIDE
39% increase in average treatments per center between 2000 and 2016 *2006 1st Leksell Gamma Knife Perfexion unit installed **2015 1st Leksell Gamma Knife Icon unit installed

6 Leksell Gamma Knife® AVERAGE NUMBER OF TREATMENTS PER REGION & CENTER
Average number of treatments per center worldwide: 309 204 centers reported their data *Perfexion and Icon Centers

7 Leksell Gamma Knife® DISTRIBUTION OF TREATMENTS BY REGION 2016
94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

8 Leksell Gamma Knife® GLOBAL CASE MIX BY YEAR
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

9 Leksell Gamma Knife® CASE MIX FOR 1968 - 2016 BY REGION
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

10 Leksell Gamma Knife® CASE MIX FOR 2016 BY REGION
94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

11 Leksell Gamma Knife® TREATMENTS BY INDICATION 1968 – 2016, WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

12 Leksell Gamma Knife® TREATMENT COMPARISON BY INDICATION CATEGORY
The percentage of centers submitting their numbers has varied between 80-95% from 2011 to 2016

13 Leksell Gamma Knife® INDICATIONS TREATED 1968 – 2016, WORLDWIDE
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 **Meningioma Grade I & II treatments reported as Meningioma prior to 2015 ***Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 ****Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

14 Leksell Gamma Knife® TREATMENTS BY INDICATION 2016, WORLDWIDE
94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

15 INDICATIONS TREATED 2016, WORLDWIDE
Leksell Gamma Knife® INDICATIONS TREATED 2016, WORLDWIDE 94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

16 Leksell Gamma Knife® CASE MIX BY COUNTRY 2016, 9 LARGEST MARKETS
CHINA TAIWAN SOUTH KOREA 2%

17 Leksell Gamma Knife® CASE MIX BY COUNTRY 2016, 9 LARGEST MARKETS
JAPAN INDIA UNITED STATES

18 Leksell Gamma Knife® CASE MIX BY COUNTRY 2016, 9 LARGEST MARKETS
TURKEY ITALY UNITED KINGDOM

19 Leksell Gamma Knife® MULTI-SESSION 2016
INDICATIONS TREATED DISTRIBUTION OF SESSIONS 105 centers reported multi- session treatment data

20 Leksell Gamma Knife® INDICATIONS TREATED (MULTI-SESSION) 2016
105 centers reported multi- session treatment data

21 Treatments with LEKSELL GAMMA KNIFE®
Indication Specific Statistics

22 BENIGN TUMORS, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® BENIGN TUMORS, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

23 BENIGN TUMORS TREATED ANNUALLY, WORLDWIDE
Leksell Gamma Knife® BENIGN TUMORS TREATED ANNUALLY, WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

24 BENIGN TUMORS, PATIENTS TREATED WORLDWIDE CUMULATIVE
Leksell Gamma Knife® BENIGN TUMORS, PATIENTS TREATED WORLDWIDE CUMULATIVE *Meningioma Grade I & II treatments reported as Meningioma prior to 2015 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

25 BENIGN TUMORS, PATIENTS TREATED WORLDWIDE 2016
Leksell Gamma Knife® BENIGN TUMORS, PATIENTS TREATED WORLDWIDE 2016 94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

26 MENINGIOMA, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® MENINGIOMA, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

27 VESTIBULAR SCHWANNOMA, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® VESTIBULAR SCHWANNOMA, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

28 PITUITARY ADENOMAS, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® PITUITARY ADENOMAS, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

29 Leksell Gamma Knife® FUNCTIONAL DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

30 Leksell Gamma Knife® FUNCTIONAL DISORDERS TREATED ANNUALLY, WORLDWIDE
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

31 Leksell Gamma Knife® FUNCTIONAL DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 ** Epilepsy treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

32 FUNCTIONAL DISORDERS, PATIENTS TREATED 2016 WORLDWIDE
Leksell Gamma Knife® FUNCTIONAL DISORDERS, PATIENTS TREATED 2016 WORLDWIDE 94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

33 TRIGEMINAL NEURALGIA, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® TRIGEMINAL NEURALGIA, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

34 Leksell Gamma Knife® FUNCTIONAL DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE EXCLUDING TRIGEMINAL NEURALGIA The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

35 Leksell Gamma Knife® FUNCTIONAL DISORDERS TREATED ANNUALLY, WORLDWIDE EXCLUDING TRIGEMINAL NEURALGIA
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

36 MALIGNANT TUMORS, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® MALIGNANT TUMORS, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

37 MALIGNANT TUMORS TREATED ANNUALLY, WORLDWIDE
Leksell Gamma Knife® MALIGNANT TUMORS TREATED ANNUALLY, WORLDWIDE *Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 **Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

38 MALIGNANT TUMORS, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® MALIGNANT TUMORS, CUMULATIVE PATIENTS TREATED WORLDWIDE *Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 **Malignant Glial Tumor (Grade III & IV) treatments broken down by indication after 2014 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

39 MALIGNANT TUMORS, PATIENTS TREATED 2016 WORLDWIDE
Leksell Gamma Knife® MALIGNANT TUMORS, PATIENTS TREATED 2016 WORLDWIDE 94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

40 Leksell Gamma Knife® METASTATIC TUMOR, CUMULATIVE PATIENTS TREATED WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

41 Leksell Gamma Knife® OCULAR DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

42 OCULAR DISORDERS TREATED ANNUALLY, WORLDWIDE
Leksell Gamma Knife® OCULAR DISORDERS TREATED ANNUALLY, WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

43 Leksell Gamma Knife® OCULAR DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

44 OCULAR DISORDERS, PATIENTS TREATED 2016 WORLDWIDE
Leksell Gamma Knife® OCULAR DISORDERS, PATIENTS TREATED 2016 WORLDWIDE 94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

45 Leksell Gamma Knife® VASCULAR DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

46 Leksell Gamma Knife® VASCULAR DISORDERS TREATED ANNUALLY, WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

47 Leksell Gamma Knife® VASCULAR DISORDERS, CUMULATIVE PATIENTS TREATED WORLDWIDE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

48 VASCULAR DISORDERS, PATIENTS TREATED 2016 WORLDWIDE
Leksell Gamma Knife® VASCULAR DISORDERS, PATIENTS TREATED 2016 WORLDWIDE 94% of all Leksell Gamma Knife centers submitted their 2016 treatment data

49 ARTERIOVENOUS MALFORMATIONS, CUMULATIVE PATIENTS TREATED WORLDWIDE
Leksell Gamma Knife® ARTERIOVENOUS MALFORMATIONS, CUMULATIVE PATIENTS TREATED WORLDWIDE The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

50 Treatments with LEKSELL GAMMA KNIFE®
Asia

51 Leksell Gamma Knife® OVER 520 000 PATIENTS TREATED THROUGH 2016, ASIA
The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016

52 Leksell Gamma Knife® INDICATIONS TREATED ANNUALLY, ASIA
The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016

53 Leksell Gamma Knife® CASE MIX 1990 – 2016, ASIA
The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016

54 Leksell Gamma Knife® INDICATIONS TREATED 1990 – 2016, ASIA
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 **Meningioma Grade I & II treatments reported as Meningioma prior to 2015 ***Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 ****Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016

55 Leksell Gamma Knife® CASE MIX 2016, ASIA
99% of all Leksell Gamma Knife centers submitted their 2016 treatment data

56 Leksell Gamma Knife® INDICATIONS TREATED 2016, ASIA
99% of all Leksell Gamma Knife centers submitted their 2016 treatment data

57 Leksell Gamma Knife® OVER 185 000 PATIENTS TREATED THROUGH 2016, CHINA
The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016

58 Leksell Gamma Knife® CASE MIX, CHINA
1993 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

59 Leksell Gamma Knife® OVER 12 000 PATIENTS TREATED THROUGH 2016, INDIA
The percentage of centers submitting their numbers each year has varied between % from 1997 to 2016

60 Leksell Gamma Knife® CASE MIX, INDIA
1997 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

61 Leksell Gamma Knife® OVER 237 000 PATIENTS TREATED THROUGH 2016, JAPAN
The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016

62 Leksell Gamma Knife® CASE MIX JAPAN
1990 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

63 Leksell Gamma Knife® OVER 53 000 PATIENTS TREATED THROUGH 2016, SOUTH KOREA
The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016

64 Leksell Gamma Knife® CASE MIX SOUTH KOREA
1991 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1990 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

65 Leksell Gamma Knife® OVER 16 000 PATIENTS TREATED THROUGH 2016, TAIWAN
The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016

66 Leksell Gamma Knife® CASE MIX TAIWAN
1993 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016 *86% of all Gamma Knife centers submitted their 2016 treatment data

67 Treatments with LEKSELL GAMMA KNIFE®
North America

68 Leksell Gamma Knife® OVER 260 000 PATIENTS TREATED THROUGH 2016, NORTH AMERICA
The percentage of centers submitting their numbers each year has varied between % from 1987 to 2016 1991 reflects cumulative numbers since 1987

69 Leksell Gamma Knife® INDICATIONS TREATED ANNUALLY, NORTH AMERICA
The percentage of centers submitting their numbers each year has varied between % from 1987 to 2016 1991 reflects cumulative numbers since 1987

70 Leksell Gamma Knife® CASE MIX 1987 – 2016, NORTH AMERICA
The percentage of centers submitting their numbers each year has varied between % from 1987 to 2016

71 Leksell Gamma Knife® INDICATIONS TREATED 1987 – 2016, NORTH AMERICA
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 **Meningioma Grade I & II treatments reported as Meningioma prior to 2015 ***Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 ****Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1987 to 2016

72 Leksell Gamma Knife® CASE MIX 2016, NORTH AMERICA
86% of all Leksell Gamma Knife centers submitted their 2016 treatment data

73 Leksell Gamma Knife® INDICATIONS TREATED 2016, NORTH AMERICA
86% of all Leksell Gamma Knife centers submitted their 2016 treatment data

74 Leksell Gamma Knife® OVER 250 000 PATIENTS TREATED THROUGH 2016, UNITED STATES
The percentage of centers submitting their numbers each year has varied between % from 1987 to 2016 1991 reflects cumulative numbers since 1987

75 Leksell Gamma Knife® CASE MIX UNITED STATES
1987 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016 *86% of all Gamma Knife centers submitted their 2016 treatment data

76 Treatments with LEKSELL GAMMA KNIFE®
Latin America

77 Leksell Gamma Knife® OVER 7 200 PATIENTS TREATED THROUGH 2016, LATIN AMERICA
The percentage of centers submitting their numbers each year has varied between % from 1985 to 2016 1991 reflects cumulative numbers since 1985

78 Leksell Gamma Knife® INDICATIONS TREATED ANNUALLY, LATIN AMERICA
The percentage of centers submitting their numbers each year has varied between % from 1985 to 2016 1991 reflects cumulative numbers since 1985

79 Leksell Gamma Knife® CASE MIX 1985 – 2016, LATIN AMERICA
The percentage of centers submitting their numbers each year has varied between % from 1985 to 2016

80 Leksell Gamma Knife® INDICATIONS TREATED 1985 – 2016, LATIN AMERICA
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 **Meningioma Grade I & II treatments reported as Meningioma prior to 2015 ***Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 ****Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1985 to 2016

81 Leksell Gamma Knife® CASE MIX 2016, LATIN AMERICA
60% of all Leksell Gamma Knife centers submitted their 2016 treatment data

82 Leksell Gamma Knife® INDICATIONS TREATED 2016, LATIN AMERICA
60% of all Leksell Gamma Knife centers submitted their 2016 treatment data

83 Treatments with LEKSELL GAMMA KNIFE®
Europe

84 Leksell Gamma Knife® OVER 225 000 PATIENTS TREATED THROUGH 2016, EUROPE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

85 Leksell Gamma Knife® INDICATIONS TREATED ANNUALLY, EUROPE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016 1991 reflects cumulative numbers since 1968

86 Leksell Gamma Knife® CASE MIX 1968 – 2016, EUROPE
The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

87 Leksell Gamma Knife® CUMULATIVE INDICATIONS TREATED 1968 – 2016, EUROPE
*Essential Tremor treatments reported as Other Functional Disorders prior to 2012 **Meningioma Grade I & II treatments reported as Meningioma prior to 2015 ***Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 ****Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1968 to 2016

88 Leksell Gamma Knife® CASE MIX 2016, EUROPE
100% of all Leksell Gamma Knife centers submitted their 2016 treatment data

89 Leksell Gamma Knife® INDICATIONS TREATED 2016, EUROPE
100% of all Leksell Gamma Knife centers submitted their 2016 treatment data

90 Leksell Gamma Knife® OVER 29 000 PATIENTS TREATED THROUGH 2016, ITALY
The percentage of centers submitting their numbers each year has varied between % from 1991 to 2016

91 Leksell Gamma Knife® CASE MIX ITALY
1991 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1993 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

92 Leksell Gamma Knife® OVER 28 000 PATIENTS TREATED THROUGH 2016, TURKEY
The percentage of centers submitting their numbers each year has varied between % from 1997 to 2016

93 Leksell Gamma Knife® CASE MIX TURKEY
1997 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1997 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

94 Leksell Gamma Knife® OVER 26 000 PATIENTS TREATED THROUGH 2016, UNITED KINGOM
The percentage of centers submitting their numbers each year has varied between % from 1991 to 2016

95 Leksell Gamma Knife® CASE MIX UNITED KINGDOM
1991 – 2016 2016* The percentage of centers submitting their numbers each year has varied between % from 1997 to 2016 *100% of all Gamma Knife centers submitted their 2016 treatment data

96 Treatments with LEKSELL GAMMA KNIFE®
Middle East & Africa

97 Leksell Gamma Knife® OVER 22 000 PATIENTS TREATED THROUGH 2016, MIDDLE EAST & AFRICA
The percentage of centers submitting their numbers each year has varied between % from 1996 to 2016

98 Leksell Gamma Knife® INDICATIONS TREATED ANNUALLY, MIDDLE EAST & AFRICA
The percentage of centers submitting their numbers each year has varied between % from 1996 to 2016

99 Leksell Gamma Knife® CASE MIX 1996 – 2016, MIDDLE EAST & AFRICA
The percentage of centers submitting their numbers each year has varied between % from 1996 to 2016

100 Leksell Gamma Knife® CUMULATIVE INDICATIONS TREATED 1996 – 2016, MIDDLE EAST & AFRICA
* *Essential Tremor treatments reported as Other Functional Disorders prior to 2012 **Meningioma Grade I & II treatments reported as Meningioma prior to 2015 ***Glioblastoma reported as Malignant Glial Tumor (Grade III & IV) prior to 2015 ****Malignant Glial Tumor (Grade III & IV) treatments broken down by indication from 2015 The percentage of centers submitting their numbers each year has varied between % from 1996 to 2016

101 Leksell Gamma Knife® CASE MIX 2016, MIDDLE EAST & AFRICA
88% of all Leksell Gamma Knife centers submitted their 2016 treatment data

102 Leksell Gamma Knife® INDICATIONS TREATED 2016, MIDDLE EAST & AFRICA
* 88% of all Leksell Gamma Knife centers submitted their 2016 treatment data

103

Download ppt "Leksell Gamma Knife® Treatment Statistics Report"

Similar presentations

3 by 5 progress December 2005 Progress on global access to HIV antiretroviral therapy | 12 April 2015 2 |2 | Antiretroviral therapy coverage in low-

"3 by 5" progress December 2005 Progress on global access to HIV antiretroviral therapy | 12 April |2 | Antiretroviral therapy coverage in low-
Distribution of LDCs and MDCs

Distribution of LDCs and MDCs
00003-E-1 – December 2004 Global summary of the HIV and AIDS epidemic, December 2004 The ranges around the estimates in this table define the boundaries.

00003-E-1 – December 2004 Global summary of the HIV and AIDS epidemic, December 2004 The ranges around the estimates in this table define the boundaries.
J. Frankel, Harvard1 Emission paths implied by target formulas The 11 regions: EUROPE = –Old Europe + –New Europe US = The United States KOSAU = Korea.

J. Frankel, Harvard1 Emission paths implied by target formulas The 11 regions: EUROPE = –Old Europe + –New Europe US = The United States KOSAU = Korea.
Stereotactic surgery Radiosurgery Gamma Knife

Stereotactic surgery Radiosurgery Gamma Knife
Figure 14.1 Economic Growth in the ADE/ASR model.

Figure 14.1 Economic Growth in the ADE/ASR model.
The Trust Fund for Statistical Capacity Building General Information The trust fund (TFSCB) is a multi-donor trust fund which was launched in 1999, and.

The Trust Fund for Statistical Capacity Building General Information The trust fund (TFSCB) is a multi-donor trust fund which was launched in 1999, and.
*United States estimate based on Q1 2010 monthly average. For all of the most current estimates of U.S. cross-platform video consumption, please refer.

*United States estimate based on Q monthly average. For all of the most current estimates of U.S. cross-platform video consumption, please refer.
1 Overview of Gamma Knife ® Surgery Dr. Sandra Vermeulen, M.D. Swedish Cancer Institute Northwest Hospital Gamma Knife Center Seattle, Washington Learn.

1 Overview of Gamma Knife ® Surgery Dr. Sandra Vermeulen, M.D. Swedish Cancer Institute Northwest Hospital Gamma Knife Center Seattle, Washington Learn.
Stereotactic Gamma Knife Raiodusrgery For Vestibular Schwannoma Ming-Hsi Sun Hung-Chuan PanChiung-Chyi Shen Neurosurgery Taichung Veterans General Hospital.

Stereotactic Gamma Knife Raiodusrgery For Vestibular Schwannoma Ming-Hsi Sun Hung-Chuan PanChiung-Chyi Shen Neurosurgery Taichung Veterans General Hospital.
Gender and Development

Gender and Development
THE ECONOMICS OF FOOD Disparity; Cycle of poverty; 1 st and 3 rd world gap.

THE ECONOMICS OF FOOD Disparity; Cycle of poverty; 1 st and 3 rd world gap.
REGIONS OF THE WORLD A COLLECTION OF MAPS!.

REGIONS OF THE WORLD A COLLECTION OF MAPS!.
Patients Treated with Leksell Gamma Knife ® 1968-2014.

Patients Treated with Leksell Gamma Knife ®
The Global Economic Environment The Coming Boom Wealthy Industrial Countries2.92.7 Developing Countries3.04.8 East Asia7.57.6 South Asia4.85.3 Latin America2.63.4.

The Global Economic Environment The Coming Boom Wealthy Industrial Countries Developing Countries East Asia South Asia Latin America
Internet usage information comes from data published by   NNielsen//NetRatings,

Internet usage information comes from data published by   NNielsen//NetRatings,
Incidence Hepatocellular Carcinoma is one of the most common malignancies worldwide More common in Asia and Africa than in the United States. The highest.

Incidence Hepatocellular Carcinoma is one of the most common malignancies worldwide More common in Asia and Africa than in the United States. The highest.
Chapter 19 Global Population Projections. Predicting the Future Many attempts using economic forecasting, political forecasting, and forecasting using.

Chapter 19 Global Population Projections. Predicting the Future Many attempts using economic forecasting, political forecasting, and forecasting using.
CATCH UP AND EMERGING DIVERGENCES: Can it Reduce Inequality? Deepak Nayyar Institute of Social Studies The Hague 8th October 2015.

CATCH UP AND EMERGING DIVERGENCES: Can it Reduce Inequality? Deepak Nayyar Institute of Social Studies The Hague 8th October 2015.
Entertainment Mid Range Plan Strategy Towards Emerging Market Sony Corp. Corporate Planning & Control Division September 30, 2010.

Entertainment Mid Range Plan Strategy Towards Emerging Market Sony Corp. Corporate Planning & Control Division September 30, 2010.

Similar presentations

Ads by Google